As­traZeneca, Dai­ichi Sankyo un­cork new TNBC da­ta for 2nd part­nered ADC — and it's adding more heat un­der Gilead­'s Trodelvy

Af­ter the ap­proval of their part­nered an­ti-HER2 an­ti­body-drug con­ju­gate ear­li­er this year, As­traZeneca and Dai­ichi Sankyo are rid­ing high on the promise of their bloom­ing part­ner­ship. Now a sec­ond ADC is show­ing promise in hard-to-treat breast can­cer, and the com­pa­nies have their eyes set on their on­ly ap­proved com­peti­tor in the space.

As­traZeneca and Dai­ichi Sankyo’s next-gen ADC datopotam­ab derux­te­can post­ed a 43% re­sponse rate and five con­firmed com­plete or par­tial re­spons­es among 21 pa­tients with triple-neg­a­tive breast can­cer, ac­cord­ing to co­hort da­ta from the TRO­PI­ON-Pan­Tu­mor01 Phase I study pre­sent­ed Sat­ur­day at the vir­tu­al ES­MO Breast an­nu­al meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.